73 Strings Announces Series A Funding Led by Blackstone and Fidelity International Strategic Ventures
73 Strings, the pioneering provider of valuation and portfolio monitoring solutions for the private capital industry, has completed its Series A funding round. The investment was led by Blackstone Innovations Investments, Blackstone's early-stage strategic investment arm, and Fidelity International Strategic Ventures (“FISV”), with participation from Broadhaven Ventures.
73 Strings is trusted by some of the world’s largest multi-strategy alternative investment firms across North America, Europe, and the Middle East with a client base that spans pension funds, sovereign wealth funds, limited partners (LPs), and general partners (GPs), including Eurazeo in France (€35B AUM), and Sofina in Belgium (€9B+ AUM). Today, the company’s platform is leveraged by clients with a combined AUM of over $2 trillion across Private Equity, Growth Equity, Venture Capital, and Private Credit strategies. 73 Strings will use the capital to continue to invest in building the product, engineering, and go-to-market teams.
“In a complex and volatile environment, it’s increasingly critical to alternative asset managers and their investors to deliver fast, frequent, and efficient valuations. This process is critical to keeping stakeholders well-informed. We’re enabling our customers to extract more information, intelligence, and value out of the portfolio monitoring and valuations process. We are thrilled to have the support of prestigious investors including Blackstone, FISV, and Broadhaven Ventures,” said Yann Magnan, co-founder and Chief Executive Officer at 73 Strings.
“With this funding, we are well-positioned to continue providing best-in-class technology solutions to the private capital industry. Our diverse skill sets and global footprint enable us to deliver products that shape the future of the industry,” said Abhishek Pandey, co-founder of 73 Strings.
The rapid growth and complexity of the alternatives industry increasingly requires scalable middle-office technology that can support the rise in the number of private investments within LP and GP portfolios. 73 Strings allows funds to move away from error-prone spreadsheets into a scalable software solution that streamlines the collection of portfolio company data and allows users to run automated valuations processes for private assets. The company’s integrated solution introduces efficiency, better risk management, and enhanced quality control to the portfolio monitoring and valuations processes.
“Blackstone knows firsthand that the growth of the alternatives industry and the innovation around new investment products requires scalable technology solutions. Valuations and portfolio monitoring are two of the most critical workflows in the private capital industry, and we believe there is a significant opportunity to introduce automation and efficiency into these areas. We’re thrilled to partner with Yann, Abhishek, and the 73 Strings team to further the platform’s growth and product development,” said Stevi Petrelli, Head of Blackstone Innovations Investments.
“Software has not kept pace with the dramatic increase in demand for private assets over the last decade. With 73 Strings’ unique combination of technology and private assets expertise, managers can scale efficiently and transform the drudgery of manual data entry into automated digital workflows. Digitizing private assets operations will unlock productivity, transparency, and ultimately enable greater liquidity. We are excited to partner with the team and support their mission to transform the alternative investment industry,” said Alokik Advani, Managing Partner, FISV.
About 73 Strings
73 Strings is a modern, integrated and holistic data collection, monitoring and valuation platform powering the private capital industry. The company has developed a next generation AI-powered platform to assist alternative investment funds in streamlining their middle-office processes. The platform enables funds to collect and seamlessly structure portfolio company data, monitor these companies and estimate their fair value at the click of a button. 73 Strings supports clients globally across multiple strategies including Private Equity, Growth Equity, Venture Capital and Private Credit.
Since inception, 73 Strings has added clients with combined assets under management of more than USD 2 trillion. The company is headquartered in Paris and has a global presence across New York, London, Paris, Toronto, and Bengaluru to support its growing customer base. The current leadership of 73 Strings has extensive professional expertise in private assets and the team is supported by a global network of highly seasoned advisors with a combined 300+ years of financial advisory and private markets experience.
For more information, please visit 73strings.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230712170673/en/
Contact information
Media Inquiries
morgan@bevelpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress29.9.2023 20:43:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin. “We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community." Key abstracts from Incyte-sponsored programs include: Late-breaking Oral Presentations Vitiligo Efficacy an
Q4 Inc. Recognized as one of Canada’s Top Growing Companies by The Globe and Mail29.9.2023 17:30:00 EEST | Press release
Q4 Inc. (TSX: QFOR) (“Q4” or “the Company”), the leading capital markets access platform, is pleased to announce their ranking on the 2023 Report on Business of Canada’s Top Growing Companies. Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Q4 earned its spot with three-year growth of 150%. “We are honored to be recognized as one of Canada’s Top Growing Companies for the fourth consecutive year by The Globe and Mail,” remarked Darrell Heaps, Founder and CEO of Q4. “We are proud of the growth we have achieved as a company and this recognition is a true reflection of our dedication to helping our clients win in the capital markets through innovative technology on the Q4 Platform.” Canada’s Top Growing Companies is an editorial ranking that was launched in 2019. It aims to bring the accomplishments of innovative businesses in Canada to the forefront. In order to qualify for this voluntary program; companies had to complete an in-depth application proc
GEDi Cube and Renovaro Biosciences Sign Definitive Agreement to Combine29.9.2023 16:15:00 EEST | Press release
GEDi Cube Intl Ltd. (GEDi Cube), an AI medical technology company, and Renovaro Biosciences Inc. (NASDAQ:RENB) (Renovaro), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy, have signed a definitive agreement to combine, in which GEDi Cube will become a wholly-owned subsidiary of Renovaro in a stock-for-stock acquisition (the “Transaction”). If completed, the Transaction will result in a combined company that will offer advanced early diagnosis and early identification of recurring cancer as well as potential therapies for several critical diseases such as pancreatic cancer and other solid tumors with poor life expectancy. The combined company will have a unique advantage: Renovaro Biosciences’ pre-clinical and clinical trial data could be utilized to accelerate GEDi Cube’s AI capabilities that, in turn, could potentially help to accelerate Renovaro’s development of potential new therapies. AI will be used to advance the fields of diagnosis and treatment with
Offshore Windfarm Hollandse Kust Zuid Inaugurated29.9.2023 14:53:00 EEST | Press release
Today, Dutch King Willem-Alexander jointly with the board members of Vattenfall, BASF, and Allianz officially inaugurated the offshore wind farm Hollandse Kust Zuid 1-4. The wind farm is in the North Sea, 18-36 kilometers off the Dutch coast between the towns of Scheveningen and Zandvoort. The 139 turbines have a total capacity of 1.5 GW, making it one of the largest offshore wind farms in the world. The annual electricity production is expected to equal the consumption of 1.5 million households. Hollandse Kust Zuid is owned by Vattenfall, BASF, and Allianz. The wind farm is expected to be fully operational in 2024 and will be serviced out of the port of IJmuiden. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230929518869/en/ Inauguration Hollandse Kust Zuid wind farm. From left to right: Helene Biström (Senior Vice President, Head of Business Area Wind Vattenfall), Martijn Hagens (CEO Vattenfall Netherlands), His Majesty K
The Estée Lauder Companies Launches 2023 Breast Cancer Campaign: Beautifully United to Help End Breast Cancer29.9.2023 14:00:00 EEST | Press release
For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all. This October, The Estée Lauder Companies (ELC) honors Breast Cancer Awareness Month by launching The Campaign in support of the global breast cancer community. As ELC’s largest corporate social impact program, The Campaign continues to inspire purpose-driven action and is a cornerstone of the company’s social investments in women’s advancement, health and education. Through The Campaign, ELC has also been a longstanding supporter of women in science, research and medicine – funding numerous grants and programs around the world and accelerating opportunities for women in STEM. The Campaign was founded by Evelyn H. Lauder in 1992 with the launch of the iconic Pink Ribbon. At a time when breast cancer wasn’t spoken about openly, Evelyn and ELC saw an opportunity to bring awareness to the disease and address stigmas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom